571 results about "Fibroblast" patented technology

The invention belongs to the technical field of biotechnology and animal models, and discloses a double-person-derived mouse model for simulating a tumor immune microenvironment and a construction method and application thereof. The method comprises the following steps: firstly, pretreating NSG immunodeficient mice by adopting low-dose whole-body irradiation in combination with double-antibody targeted bone marrow depletion, and transplanting CD34 + hematopoietic stem cells from the same human donor to complete human immune system reconstruction; separating tumor primary cells, tumor-related fibroblasts and tumor vascular endothelial cells of the same donor, performing three-dimensional co-culture to obtain homologous human tumor organs, and performing in-situ inoculation to immune reconstruction mice to obtain a target model. The core defects of MHC mismatching, low immune reconstruction efficiency, poor tumor immune microenvironment simulation degree, low clinical consistency and the like of an existing model are overcome, and the method can be used for tumor immune treatment drug screening, microenvironment mechanism research and personalized tumor treatment scheme verification.

The invention belongs to the technical field of biological medicine, and particularly relates to recombinant human XVII micromolecular collagen as well as a preparation method and application thereof. According to the invention, a recombinant human XVII type micromolecular collagen (Re-Hcol17) is constructed, and a stable triple helix structure is formed by connecting the 15th collagen domain, the 12th collagen domain, the 5th collagen domain and the 1st collagen domain in series. Experimental results prove that the Re-Hcol17 can significantly promote NIH / 3T3 fibroblast proliferation within the concentration range of 10-100 [mu] g / mL, the effect is better than that of natural human collagen, and extracellular matrix adhesion can be effectively promoted. Through genetic engineering and fermentation process innovation, the bottleneck that the human-derived XVII type collagen is difficult to efficiently express and unstable in structure is broken through, and a foundation is laid for wide application of the human-derived XVII type collagen in the fields of biological medicines and cosmetics.

The invention relates to the technical field of medicines, in particular to application of alpha-ketoglutaric acid in preparation of a medicine for preventing and / or treating myopia. The invention provides application of alpha-ketoglutaric acid or pharmaceutically acceptable salt thereof in preparation of products for preventing and / or treating myopia, and the alpha-ketoglutaric acid is taken as an important intermediate metabolite of tricarboxylic acid cycle in mitochondrial aerobic respiration and has oral safety; researches show that alpha-ketoglutaric acid can inhibit myopia progress and ocular axis elongation by improving sclera fibroblast phenotype transformation and extracellular matrix remodeling, and a new idea is provided for preparation of myopia intervention drugs.

The invention relates to an anti-wrinkle and anti-aging composition and application thereof. The anti-wrinkle and anti-aging composition is prepared from hydrolyzed rice protein, a bifidus yeast fermentation product lysate, dipeptide diaminobutyryl benzyl amide diacetate, adenosine, hydroxydecyl ubiquinone, ceramide NP, palmitoyl tripeptide-5, carnosine and acetyl hexapeptide-8. According to the present invention, the components achieve the synergistic effect, such that the fibroblast proliferation can be promoted, the cell metabolism can be improved, the generation of collagen, elastin and the like can be promoted, the excellent oxidation resistance can be provided, and the effects of expression line inhibition, existing wrinkle fading and long-term aging resistance can be combined.

The invention discloses application of sauchinone in cardiac fibrosis, relates to the technical field of medicines, and particularly relates to application of pharmaceutically acceptable salt derivatives of sauchinone in preparation of medicines for treating and / or relieving cardiac fibrosis. The sauchinone disclosed by the invention inhibits proliferation and migration of fibroblasts induced by Ang II. The sauchinone has a potential anti-cardiac fibrosis effect. The sauchinone can reduce the area of cardiac fibrosis and down-regulate mRNA level and protein expression of fibrosis related indexes, so that the sauchinone shows a potential anti-fibrosis effect.

The invention relates to the technical field of compound preparation and medicine, in particular to a boron atom-labeled compound for targeting fibroblast activating protein as well as a preparation method and application of the boron atom-labeled compound. The preparation method comprises the following steps: carrying out acid amine condensation on (4-(((2, 5-dioxopyrrolidine-1-yl) oxy) carbonyl) phenyl) boric acid and an FAP targeting ligand to obtain a boron atom-labeled compound targeting the fibroblast activating protein; and the FAP targeting ligand is FAPI-46 or FAP-2286 (Fibroblast Amplified Polymorphism). The compound is easy to prepare, high in purity and good in stability, the content of boron atoms in tumor tissue can be greatly increased, and a treatment basis is provided for boron neutron capture therapy.

The invention discloses a medicine composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) through a chemical small molecule combination, and the medicine composition is used for treating sepsis. According to the invention, a chemical reprogramming strategy without genetic modification is adopted, an endogenous signal channel is activated through a time sequence, and fibroblasts from somatic cells are efficiently converted into PCLCs with high expression of genes such as EMILIN3, LAMC3, GDF10, AHR, CD109, AHR, NQO1, QPRT and the like. When applied to treatment of sepsis, the medicine composition can improve pathological symptoms and reduce death rate by synergistically exerting anti-inflammatory, anti-oxidation, immune regulation and tissue barrier protection effects. The invention provides a novel safe treatment strategy based on non-genetically modified cells for sepsis.

The invention discloses a rhodotorula mucilaginosa strain as well as a fermentation product filtrate and a biological product thereof, and belongs to the technical field of microorganisms. The rhodotorula mucilaginosa BTN-HB-L28 strain is separated and purified from meconopsis in Lijiang of Yunnan, can be used in the field of cosmetics, has the effects of resisting skin oxidation, resisting aging, repairing skin and relieving skin, can be used as an active matter in skin care products, and has practical application value. The fermentation product filtrate of the strain has excellent HAS inhibition ability, and can significantly inhibit the expression of matrix metalloproteinase 3; the fibroblast proliferation can be obviously promoted under various concentrations; the proportion of SA-beta-Gal positive cells can be remarkably reduced under various concentrations, and the anti-aging effect is achieved; the antioxidant composition has remarkable DPPH and ABTS free radical scavenging capacity and has a good antioxidant effect; the secretion amount of cell inflammatory factors NO, IL-6 and TNF-alpha can be remarkably inhibited, and the good relieving effect is achieved.

The present disclosure relates to pharmaceutical compositions comprising a [61Cu]Cu-labeled fibroblast activation protein (FAP) inhibitor-NODAGA conjugate. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a FAP-expressing cancer or tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

The invention relates to the technical field of biomedical materials, in particular to a degradable zinc-based composite GBR film with the surface loaded with a nanometer electrostatic spinning fiber coating and preparation and application of the degradable zinc-based composite GBR film. According to the degradable zinc-based composite GBR membrane with the surface loaded with the nano electrostatic spinning fiber coating, the nano fiber coating is implanted into the surface of a zinc-based material such as zinc alloy by adopting an electrostatic spinning technology, and the degradable zinc-based composite GBR membrane with the surface loaded with the nano electrostatic spinning fiber coating can inhibit excessive release of zinc ions, improve biocompatibility of the zinc alloy and the like, promote osteoblast differentiation and promote angiogenesis. The electrostatic spinning coating on the surface of the zinc-based composite GBR membrane serves as a physical barrier to block invasion of epithelial cells and fibrocytes, and angiogenesis is promoted along with degradation of fibers and slow release of drugs; the porous zinc alloy and the like in the middle layer not only provide mechanical support, but also release zinc ions in the degradation process to achieve multiple functions of resisting bacteria and promoting osteogenesis.

The invention provides an anti-aging composition containing schizophyllan, a medical beauty injection preparation and application of the anti-aging composition and the medical beauty injection preparation, the anti-aging composition comprises hyaluronic acid or salt of the hyaluronic acid, the schizophyllan and mannitol, and the mass ratio of the hyaluronic acid or the salt of the hyaluronic acid to the schizophyllan to the mannitol is (0.2-3): (0.01-0.5): (0.5-5). According to the anti-aging composition disclosed by the invention, through the multi-component synergistic effect of the schizophyllatin, the hyaluronic acid or the salt thereof and the mannitol, the proliferation activity of fibroblasts can be remarkably improved, and the synthesis and expression of collagen can be efficiently promoted, so that the depth and the quantity of skin wrinkles are effectively improved, and the compactness and the elasticity of the skin are remarkably enhanced; the comprehensive skin rejuvenation effect is realized.

The invention discloses a recombinant III-type collagen and PDRN compound composition and a preparation method thereof, and relates to the technical field of biological medicines. The composition is formed by compounding recombinant human III type collagen and polydeoxyribonucleotide according to the mass ratio of 1: 10-10: 1, the weight-average molecular weight of the recombinant human III type collagen and the weight-average molecular weight of the polydeoxyribonucleotide are 50-100 kDa, the ratio can generate synergistic interaction, fibroblast proliferation, migration and collagen secretion are remarkably promoted, and the activity of the composition is superior to that of a single component and commercially available products. The composition can be used for preparing medical instruments, cosmetics or water-light injections for skin repair, rejuvenation or skin improvement. The invention also provides a water-light injection containing the compound composition, and the obtained preparation is stable, clear, transparent, safe and non-irritant.

The invention discloses application of piperlongumine in preparation of a medicine for treating virus-induced myocardial fibrosis. According to the application, an in-vivo myocardial fibrosis model is constructed by infecting a BALB / c mouse with a CVB3 virus, and meanwhile, an in-vitro cell model for proliferation and differentiation of primary myocardial fibroblasts is constructed by inducing TGF-beta1. Results prove that when the piperlongumine is applied to the acute stage (1-14 days), the chronic stage (14-28 days) and the whole course (1-28 days) of the viral myocarditis, the myocardial fibrosis of the viral myocarditis can be remarkably improved, the cardiac function is improved, and the curative effect of the piperlongumine applied to the whole course is superior to that of the piperlongumine applied to the acute stage and the chronic stage; the specific mechanism is that Smad2 / 3 and p-38 / YAP pathways jointly play a role in inhibiting myocardial fibrosis.

The invention belongs to the field of biomedicine, and provides application of LDHA as a treatment target of aging-related osteoarthritis. In-vitro cell experiments and animal in-vivo experiments prove that the LDHA inhibitor can inhibit OA progress caused by aging, and targeted inhibition of LDHA in synovial fibroblasts can provide a brand-new treatment strategy for treatment of aging-related osteoarthritis.

Embodiments of the disclosure include methods and compositions for the treatment of splenomegaly. In specific embodiments, fibroblasts and / or fibroblast-derived materials, are utilized in at least some cases to affect the immune response of the individual in order to reduce the pathogenic levels of immune cells or cytokines and / or chemokines excreted by those immune cells.

The invention provides an application of pentafluridol in preparation of a medicine for inhibiting formation of tumor-associated fibroblasts. Specifically, the invention finds that the pentafluridol can influence the formation process of the tumor microenvironment of the targeted tumor-related fibroblast cells, and the development of solid tumors is effectively inhibited from the source, so that the increase of the tumor volume is inhibited.

The invention relates to the technical field of organoid culture, in particular to a pulmonary fibrosis organoid model and a construction method and application thereof. The pulmonary fibrosis organ-like model is obtained by co-culturing lentivirus stably transfected alveolar epithelial cells, human embryonic lung fibroblasts MRC-5 and macrophages. According to the invention, macrophages are innovatively introduced, a ternary co-culture system of lentivirus stably transfected alveolar epithelial cells, human embryonic lung fibroblasts MRC-5 and macrophages is constructed, and a key'epithelial injury-immune infiltration-fibroblast activation 'pathological triangle in a pulmonary fibrosis pathogenesis process can be more comprehensively simulated; the finally obtained pulmonary fibrosis organ-like model provides an efficient tool for pulmonary fibrosis mechanism research and research, development and screening of anti-pulmonary fibrosis drugs.

Provided are a pharmaceutical composition and a preparation method therefor. Specifically, provided are an aqueous pharmaceutical composition of a radionuclide-labeled fibroblast activation protein-targeting ligand, and a preparation method therefor. The aqueous pharmaceutical composition has high radiochemical purity.

The present disclosure concerns genetic modification of fibroblasts or fibroblast-derived materials (including of the fibroblasts from which the fibroblast-derived materials are derived). In specific aspects, they are modified such that they may express one or more surface markers that allow targeting to a tissue and / or organ of interest. In some aspects, they are modified such that they may lose one or more surface markers that then allow targeting to a tissue and / or organ of interest. In certain aspects, one or more surface markers are modified that then allows targeting to a tissue and / or organ of interest.

The invention discloses an application of samidocardone in preparation of a medicine for treating pulmonary fibrosis. According to the application disclosed by the invention, the condition that the samidojun can inhibit the activity of the pulmonary fibrosis cells and reduce proliferation by inducing the ferroptosis of the pulmonary fibrosis cells is proposed and verified for the first time, and meanwhile, the expression of fibrosis-related proteins is reduced, so that the progress of the pulmonary fibrosis is effectively relieved, and a new direction is provided for treating the pulmonary fibrosis.

The application relates to application of a sesquiterpenoid compound in preparation of a medicine for preventing and / or treating pulmonary fibrosis. The sesquiterpenoid compound has obvious inhibiting collagen deposition effect on TGF-beta 1 induced human embryo lung fibroblasts, does not show cytotoxicity, has good anti-pulmonary fibrosis activity, and can be used for preparing the medicine for preventing and / or treating pulmonary fibrosis.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The application specifically relates to a breast cancer invasion and metastasis model based on anisotropic collagen hydrogel and a construction method thereof, and belongs to the technical field of biomedical materials and tumor microenvironment. The anisotropic hydrogel with highly parallel arrangement of collagen fibers is prepared by adopting a PDMS mold pre-tensioning-stress rebound process, and the orientation index is 0.62+ / -0.05. The hydrogel has high matching of mechanical properties with the breast cancer microenvironment in vivo and good biocompatibility. The model can induce mature adipocytes to dedifferentiate and fibroblasts to transdifferentiate, and drive the breast cancer cells to have enhanced invasion and migration ability and EMT phenotype, and reproduce a pathological axis of "collagen orientation→adipocyte dedifferentiation→breast cancer invasion and metastasis". The process depends on the activation of a DDR1-integrin beta1-FAK-YAP signal path, and a DDR1 inhibitor can effectively reverse the above effects. The application can be used for breast cancer metastasis mechanism research and drug screening targeting the DDR1 path.

The invention discloses engineering mitochondria enriched with alpha2delta2 protein, the expression level of the alpha2delta2 protein in the mitochondria is higher than that of natural mitochondria, the expression quantity of the alpha2delta2 protein is 15-40 times that of the natural mitochondria, and the alpha2delta2 protein is enriched in the outer membrane of the mitochondria. The invention also discloses a preparation method of the engineered mitochondria enriched with the alpha2delta2 protein. The invention also discloses an application of the engineered mitochondria enriched with the alpha2delta2 protein in preparation of medicines for preventing and / or treating fibrosis diseases. In-vitro experiments prove that the engineered mitochondria can significantly enhance the ability of inhibiting fibroblast activation and collagen secretion, and the effect of the engineered mitochondria is far better than that of common mitochondria. The invention provides a brand-new and effective organelle level treatment scheme for solving the clinical problem of fibrosis.

The invention provides an aerosol-type face pack cosmetic that, when dispensed, forms a flexible, easy-to-use, and low-irritation resin foam that easily adheres to the face, such as around the eyes and nose. It also allows the fermented liquid contained in the resin foam to easily seep out, making it easy to apply the fermented liquid to the face and less likely to cause tightness. [Solution] An aerosol pack cosmetic comprising a beauty serum and dimethyl ether, wherein the beauty serum comprises at least one fermentation solution selected from Saccharomyces / Anzange ferment filtrate, Saccharomyces / Human (fibroblast / mononuclear cell) induced pluripotent cell culture conditioned medium ferment filtrate, Galactomyces / Eryngium multiflorum callus culture ferment filtrate, and a resin.

Provided are a labeled fibroblast activation protein inhibitor and a use thereof. Specifically, the present disclosure provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and the use thereof in diagnosing or treating diseases associated with fibroblast activation protein, such as tumors and cancers. Each substituent is respectively as defined in the description.

The invention provides a high-porosity and anti-adhesion tendon repair material, and relates to the field of medical biomaterials.The high-porosity and anti-adhesion tendon repair material is prepared through the following steps that animal tendons are obtained, degreased and rinsed; decellularization and rinsing are carried out; performing disinfection; performing rinsing; stretching and freeze-drying: clamping two ends by using a clamp, stretching and fixing, and freeze-drying to form pores in the tendon; soaking adsorption: taking out the freeze-dried tendon, putting the tendon into a tubular mold, pouring the anti-adhesion hydrogel precursor solution into the tubular mold, and performing soaking treatment for 12-24 hours; and performing irradiation crosslinking: performing irradiation treatment on the tubular mold filled with the tendon and the anti-adhesion hydrogel precursor solution to obtain the tendon repair material. The tendon repair material not only can effectively prevent the tendon from adhering to normal tissues, but also can control the pore size of the tendon, is beneficial to infiltration and proliferation of fibroblasts and tendons, promotes blood vessel ingrowth and metabolite exchange, and provides a good basis for tissue repair and regeneration.

The invention belongs to the field of biological medicine, and particularly relates to a YBX3 gene, a YBX3 gene inhibitor and application of the YBX3 gene inhibitor. The invention discloses application of the YBX3 gene as a biomarker in preparation of a product for detecting cardiac fibrosis. The nucleotide sequence of the YBX3 gene is as shown in SEQ ID NO. 1. The invention discloses application of a YBX3 gene inhibitor in preparation of drugs for preventing and / or treating heart diseases. The YBX3 gene inhibitor is shRNA (short hairpin ribonucleic acid) and has a nucleotide sequence as shown in SEQ ID NO. 3. When myocardial infarction occurs, mRNA and protein level expression activity of the YBX3 gene is remarkably improved and is related to fibroblast activation, and the silent YBX3 gene can remarkably inhibit fibroblast activation. The existing myocardial infarction injury medicine has a limited treatment effect, so that the YBX3 can improve the clinical prognosis of myocardial infarction injury by regulating and controlling the activation of cell fibrosis.

The present disclosure relates to a kit. The kit of the present disclosure comprises: a kit body comprising a needle tube and a needle, the first end of the needle being mounted to the needle tube; and a catabolic filling thread comprising a first segment and a second segment connected to each other, at least a part of the first segment being located inside the needle, and at least a part of the second segment being located outside the needle, wherein the catabolic filling thread is a thread made of poly-L-lactic acid. The kit of the present disclosure comprises a catabolic filling thread which can be composed of poly-L-lactic acid, is absorbable, has no residue, and is metabolized into lactic acid in the human body. Such a configuration makes the catabolic filling thread itself not only play a role in filling and tightening when filling surgery is performed using the catabolic filling thread of the present disclosure, but also the lactic acid after its metabolism can still stimulate fibroblasts in the skin and subcutaneous tissue to reconstruct the collagen framework in the human body by using fibroblasts.

The application relates to the technical field of biological medicines, in particular to a deer horn stem cell exosome as well as a preparation method and application thereof. The preparation method of the deer horn stem cell exosome comprises the following steps: S1, preparing P3-P5 generation deer horn stem cells; S2, preparing induced culture supernatant; S3, preparing crude extracted exosomes; and S4, preparing deer horn stem cell exosomes. The prepared deer horn stem cell exosome has high yield, high biological activity, can significantly promote fibroblast proliferation and collagen synthesis. Meanwhile, the exosome can effectively accelerate wound healing, has high 14d healing rate, can significantly increase the water content of the cutin layer of the skin, reduce the TEWL value, and improve the skin barrier function, provides high-quality raw materials for the research and development of skin repair products, and has a wide application prospect.